REGULATORY INTELLIGENCE·Warning Letter
Arbor Pharmaceuticals' Nymalize Oral Solution Recalled Due to Subpotency: Critical Supply Chain Implications
Arbor Pharmaceuticals initiated a Class III recall of 1,846 cartons of Nymalize (nimodipine) oral solution due to subpotency, impacting nationwide U.S. distribution. This voluntary, firm-initiated action, terminated in February 2022, underscores critical quality control vulnerabilities in neurological drug manufacturing. Procurement and regulatory teams must scrutinize supplier quality systems to mitigate supply chain disruptions and ensure patient safety.
90-Day Activity